

INTESTINAL RESEARCH

pISSN 1598-9100 • eISSN 2288-1956 https://doi.org/10.5217/ir.2018.00078-c1 Intest Res 2020;18(3):343-344

## Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

Keiji Yagisawa<sup>1</sup>, Taku Kobayashi<sup>2</sup>, Ryo Ozaki<sup>2</sup>, Shinji Okabayashi<sup>2</sup>, Takahiko Toyonaga<sup>2</sup>, Miki Miura<sup>3</sup>, Mari Hayashida<sup>3</sup>, Eiko Saito<sup>2</sup>, Masaru Nakano<sup>2</sup>, Hajime Matsubara<sup>1</sup>, Tadakazu Hisamatsu<sup>3</sup>, Toshifumi Hibi<sup>2</sup>

<sup>1</sup>Department of Pharmacy and <sup>2</sup>Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo; <sup>3</sup>The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan

https://doi.org/10.5217/ir.2018.00078 Intest Res 2019;17(1):87-93

In the version of this article initially published, Figure 2 contains errors in the content of the questionnaire. On page 89, the figure should be corrected as following.

## From:





Fig. 2. (A) Questionnaire 1: acceptability of tablets. (B) Questionnaire 2: acceptability of granules. (C) Questionnaire 3: comparison of tablets and granules. All the original questionnaires were written in Japanese. CR, controlled-release.

## To:



**Fig. 2.** (A) Questionnaire 1: acceptability of tablets. (B) Questionnaire 2: acceptability of granules. (C) Questionnaire 3: comparison of tablets and granules. All the original questionnaires were written in Japanese. CR, controlled-release.

344 www.irjournal.org